Insiders · Profile

Doyle Anthony

Chief Financial Officer at BIOCRYST PHARMACEUTICALS. Filing since 11 Aug 2020. CIK 0001808688

Company

Date

Role

Action

Amount

Of holding

14 May 2024

Chief Financial Officer

Bought

36,300

$202.19K

15.8%

15 Dec 2022

Chief Financial Officer

Sold, plan not stated

5,700

$62.13K

3.4%

23 Nov 2021

Chief Financial Officer

Bought

35,258

$440.02K

60.3%

11 Aug 2020

Chief Financial Officer

Bought

54,000

$220.32K

opened

4 decisions on file.